Roche: European Commission Approves New Indication For Pegasys
Roche said the European Commission has approved Pegasys plus Copegus for the retreatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha, either alone or in combination with ribavirin.
Although exciting advances in the treatment of hepatitis C have been made in recent years, Roche said a significant number of patients do not achieve treatment success, widely equated to cure with their first treatment. This results in a large and growing population of patients who urgently need alternative treatment solutions.
The approval provides a significantly broader indication for Pegasys and establishes a new standard of care for treatment-experienced patients with the most difficult-to-treat virus.
"This new indication for Pegasys plus Copegus is another demonstration of Roche's commitment to extend the promise of a cure to as many chronic hepatitis C patients as possible," said William Burns, Chief Executive Roche Pharmaceuticals Division.
"Our approach is to optimise and individualise treatment to increase patients' chance of success with Pegasys and Copegus, while establishing them as the backbone for combination with novel agents in development, both by Roche and through external partnerships and collaborations".
The Pegasys label for treatment-experienced patients contains several aspects of Personalised Healthcare, a major focus for Roche which seeks to tailor medicines for better disease management:
- The recommended length of Pegasys treatment for patients is based on their virus genotype and type of prior treatment. For patients with genotype 1 virus who did not respond to initial treatment with pegylated interferon and ribavirin, it is recommended that they be retreated with Pegasys for an extended period of 72 weeks. Pegasys is now the first and only pegylated interferon to be approved for a 72-week treatment duration in this patient population. For all other treatment-experienced patients, the recommended treatment period is 48 weeks.
- The label recommends that after 12 weeks of treatment, a patient's virus levels be measured to determine whether a full course of treatment is likely to result in a cure.
A large, Roche-sponsored study called REPEAT demonstrated that 72 weeks of retreatment with Pegasys plus Copegus doubled the chance of a achieving a cure, compared to 48 weeks, in patients who were prior nonresponders to PegIntron and ribavirin.
Furthermore, the study showed that 57% of patients who responded by week 12went on to achieve a cure with 72 total weeks of retreatment.
"The high predictability of response at week 12 with Pegasys plus Copegus should be an important factor when considering whether to retreat hepatitis C," said Professor Patrick Marcellin, Professor of Hepatology at the University of Paris and Head of the Viral Hepatitis Research Unit in Hôpital Beaujon, Clichy, France.
"It means that physicians and patients will be able to determine -- after only three months -- whether treatment is likely to result in a cure".
The safety profile for Pegasys plus Copegus in prior non-responders was similar to that seen in patients being treated for the first time. Further analyses of the 72-week treatment in REPEAT showed a favourable benefit/risk ratio for the longer duration, because more patients were able to achieve a cure than with 48 weeks of therapy.
Company Web Site: http://www.roche.com
-Zurich Bureau, Dow Jones Newswires; +41 43 443 8040; zurichdjnews@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/al?rnd=G8rN%2BJs%2FXaaSgxy4%2FPCYtg%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
December 04, 2008 02:00 ET (07:00 GMT)
Publié le 04 Décembre 2008 Copyright © 2008 Dowjones
Partager sur:
